AstraZeneca's China President Under Investigation by Authorities

Leon Wang, a key executive, is cooperating with Chinese authorities amid a broader probe into the pharmaceutical sector.

AstraZeneca has confirmed that Leon Wang, its China president, is under investigation by Chinese authorities, though his custody status remains unclear.
The investigation is reportedly linked to aggressive sales tactics and potential data privacy law breaches involving the company's oncology drugs.
AstraZeneca's shares fell significantly following the announcement, reflecting investor concerns over the situation.
The probe is part of China's broader anti-corruption campaign targeting the healthcare industry, including foreign companies operating in the country.
AstraZeneca, which employs around 16,000 people in China, has stated its commitment to fully cooperate with the investigation if requested.